Safety Study of Peptide Cancer Vaccine To Treat HLA-A*24-positive Advanced Small Cell Lung Cancer
NCT01069653
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
9
Enrollment
OTHER
Sponsor class
Conditions
Small Cell Lung Cancer
Interventions
BIOLOGICAL:
HLA-A*2402-restricted CDCA1 and KIF20A peptides
Sponsor
Shiga University
Collaborators
[object Object]